Past Studies
The work of the Center is carried out through clinical trials that investigate causes of substance use disorders and investigate novel treatments. These findings in these studies often affect the way treatment is delivered in actual healthcare environments. Information about the studies that are no longer being conducted may be accessed through the list below.
For more information on current research, visit the Active Studies page.
Positive Psychology Smoking Cessation Smartphone App for Nondaily Smokers Principal Investigator(s): Bettina Hoeppner, Ph.D., Susanne Hoeppner, Ph.D., Lourah Kelly, Ph.D., John F. Kelly, Ph.D. 2016—2021 Study Reference: 130323-RSG-17-021-01-CPPB The goal of this project is to develop a smartphone app to support smoking cessation in nondaily smokers using a positive psychology approach. A three-phase development process is proposed, using (1) in-depth feedback from n = 30 on our already developed Version 1.0, (2) a nation-wide pilot test of Version 2.0 (n = 90), and (3) a proof-of-concept randomized controlled trial (n = 226). Pilot Study of a Transdiagnostic, Emotion-focused Group Intervention for Young Adults with Substance Use Disorder Study Principal Investigator(s): Kate Bentley, Ph.D. 2018—2020 Training Grant Principal Investigator(s): A. Eden Evins, M.D., MPH & Nancy Rigotti, M.D. Study Reference: NIH/NIDA 5K12DA043490 (Career Development Program) The purpose of this pilot study is to examine the acceptability, feasibility, and preliminary efficacy of adding a transdiagnostic, emotion-focused, cognitive-behavioral group intervention to treatment as usual within a comprehensive outpatient addiction program for young adults (ages 18 to 26) with substance use disorder and co-occurring anxiety or depressive symptoms, suicidal ideation, or nonsuicidal self-injury. Participants (n = 50) are randomly assigned to receive the experimental group intervention plus treatment as usual or treatment as usual alone, and substance use (via timeline followback), anxiety and depressive symptoms, and emotion regulation indices are assessed at baseline and four and eight weeks after randomization. The Impact of Medicaid Plans on Access to and Quality of SUD Treatment Principal Investigator: Margarita Alegria, Ph.D. 2018—2021 Study Reference: NIH/NIDA 1R01DA044526-01A1 This project makes use of random assignment methods to study the effects of the structure of state Medicaid programs on access, patterns of care and outcomes of substance use disorder (SUD) care. It conducts stratified analysis by race/ethnicity, gender, and rurality to identify which programs and plans have better outcomes and if there are service disparities. It uses qualitative methods to help interpret results and suggest changes to policy and practice. Vignette Study Principal Investigator: John F. Kelly, Ph.D. Privately Funded This privately funded study looks at terminology and stigma, and how word choice may affect attitudes and perceptions. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VQW-765 in Patients with Performance Anxiety Principal Investigator(s): A. Eden Evins, M.D., MPH, 2021 Study Reference: Vanda Pharmaceutical The purpose of the study is to evaluate the effect of an investigational drug called VQW-765 on symptoms associated with performance anxiety and to assess the safety of VQW-765. Performance anxiety is a type of anxiety disorder characterized by excessive fear, discomfort, and self-consciousness in a variety of social situations related to performing in front of others such as public speaking. This intense and persistent fear in performance situations can result in significant impairment in almost all facets of daily life, including social activities, relationships, work, and studies. VQW-765 is an investigational drug. It is still being tested in research studies and is not approved by the U.S. Food and Drug Administration (FDA). In order to evaluate the effects of VQW-765 on social anxiety disorder symptoms and the safety of VQW-765, approximately 220 subjects will be enrolled nationwide and randomly assigned to one of two study drug groups: one group will receive VQW-765, and the other group will receive placebo.